150 related articles for article (PubMed ID: 38677583)
1. A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.
Verhoeven A; van Ertvelde J; Boeckmans J; Gatzios A; Jover R; Lindeman B; Lopez-Soop G; Rodrigues RM; Rapisarda A; Sanz-Serrano J; Stinckens M; Sepehri S; Teunis M; Vinken M; Jiang J; Vanhaecke T
Toxicology; 2024 Jun; 505():153814. PubMed ID: 38677583
[TBL] [Abstract][Full Text] [Related]
2. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.
van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M
J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407
[TBL] [Abstract][Full Text] [Related]
3. A Case Study on Integrating a New Key Event Into an Existing Adverse Outcome Pathway on Oxidative DNA Damage: Challenges and Approaches in a Data-Rich Area.
Huliganga E; Marchetti F; O'Brien JM; Chauhan V; Yauk CL
Front Toxicol; 2022; 4():827328. PubMed ID: 35573276
[TBL] [Abstract][Full Text] [Related]
4. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
[TBL] [Abstract][Full Text] [Related]
6. An integrative data-centric approach to derivation and characterization of an adverse outcome pathway network for cadmium-induced toxicity.
Sahoo AK; Chivukula N; Ramesh K; Singha J; Marigoudar SR; Sharma KV; Samal A
Sci Total Environ; 2024 Apr; 920():170968. PubMed ID: 38367714
[TBL] [Abstract][Full Text] [Related]
7. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
[TBL] [Abstract][Full Text] [Related]
8. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
[TBL] [Abstract][Full Text] [Related]
9. Investigation of a derived adverse outcome pathway (AOP) network for endocrine-mediated perturbations.
Ravichandran J; Karthikeyan BS; Samal A
Sci Total Environ; 2022 Jun; 826():154112. PubMed ID: 35219661
[TBL] [Abstract][Full Text] [Related]
10. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
Kim M; Kim SH; Choi JY; Park YJ
Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
[TBL] [Abstract][Full Text] [Related]
11. Development of a putative adverse outcome pathway network for male rat reproductive tract abnormalities with specific considerations for the androgen sensitive window of development.
Palermo CM; Foreman JE; Wikoff DS; Lea I
Curr Res Toxicol; 2021; 2():254-271. PubMed ID: 34401750
[TBL] [Abstract][Full Text] [Related]
12. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
[TBL] [Abstract][Full Text] [Related]
13. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
[TBL] [Abstract][Full Text] [Related]
14. Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action.
Moore MM; Schoeny RS; Becker RA; White K; Pottenger LH
Crit Rev Toxicol; 2018 Apr; 48(4):312-337. PubMed ID: 29431554
[TBL] [Abstract][Full Text] [Related]
15. Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole.
Luckert C; Braeuning A; de Sousa G; Durinck S; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg AACM; Rahmani R; Rajkovic A; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla S; Wollscheid B; Zucchini-Pascal N; Lampen A
Chem Res Toxicol; 2018 Aug; 31(8):784-798. PubMed ID: 29995386
[TBL] [Abstract][Full Text] [Related]
16. Semantic characterization of adverse outcome pathways.
Wang RL
Aquat Toxicol; 2020 May; 222():105478. PubMed ID: 32278258
[TBL] [Abstract][Full Text] [Related]
17. Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action.
Escher SE; Aguayo-Orozco A; Benfenati E; Bitsch A; Braunbeck T; Brotzmann K; Bois F; van der Burg B; Castel J; Exner T; Gadaleta D; Gardner I; Goldmann D; Hatley O; Golbamaki N; Graepel R; Jennings P; Limonciel A; Long A; Maclennan R; Mombelli E; Norinder U; Jain S; Capinha LS; Taboureau OT; Tolosa L; Vrijenhoek NG; van Vugt-Lussenburg BMA; Walker P; van de Water B; Wehr M; White A; Zdrazil B; Fisher C
Toxicol In Vitro; 2022 Mar; 79():105269. PubMed ID: 34757180
[TBL] [Abstract][Full Text] [Related]
18. Adverse outcome pathway from activation of the AhR to breast cancer-related death.
Benoit L; Jornod F; Zgheib E; Tomkiewicz C; Koual M; Coustillet T; Barouki R; Audouze K; Vinken M; Coumoul X
Environ Int; 2022 Jul; 165():107323. PubMed ID: 35660951
[TBL] [Abstract][Full Text] [Related]
19. [Molecular Pathway and AOP Development Using Gene Network Analysis].
Tanabe S; Hirose A; Whelan M; Yamada T
Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
[TBL] [Abstract][Full Text] [Related]
20. Adverse outcome pathway (AOP) development I: strategies and principles.
Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
